10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares in oncology specialist Merrimack Pharmaceuticals closed 16% down on Friday after the US company announced that it was discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. 8 April 2019
The research phase of the RNAi therapeutics collaboration between Sanofi and Alnylam Pharmaceuticals is over, the companies have announced. 8 April 2019
Japanese pharma major Eisai says that its in-house discovered fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor E7090 has been granted the Sakigake designation by Japan’s Ministry of Health, Labor and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion. 8 April 2019
Chinese biotechs will seek more cross-border licensing deals in the coming years, especially for early-stage assets, said speakers at the annual China Healthcare Investment Conference (CHIC) held in late March in Shanghai. 8 April 2019
US biotech major Celgene and Acceleron Pharma today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, 8 April 2019
The European Medicines Agency has granted a PRIME (PRIority MEdicines) designation for the investigational B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, JNJ-68284528 (JNJ-4528). 5 April 2019
Bristol-Myers Squibb has secured a positive reimbursement decision for its Opdivo (nivolumab) plus Yervoy (ipilimumab) combination, for use against kidney cancer, in the UK. 5 April 2019
Switzerland-based Roivant Sciences today announced the launch of Cytovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia, together with its previously spun-out “vant” company Sinovant Sciences. 4 April 2019
Investors in USA-based AVEO Oncology appear to be fearing the worst after the future of the company’s lead candidate was thrown into doubt. 4 April 2019
Biogen and Novartis have been given a reminder of their responsibility to patients in pricing their spinal muscular atrophy (SMA) therapies in the USA. 4 April 2019
Major US insurer Cigna has moved to cap insulin prices for customers, together with its new acquisition Express Scripts, a pharmacy benefits manager (PBM). 4 April 2019
French privately-held biotech firm Enterome Bioscience has named Jan Fagerberg its new chief medical officer and Catherine Mathis its chief development officer. 3 April 2019
Daniel Welch, the man who previously headed up several biotechs that were sold to pharma majors over the past several years, has joined privately-held US biopharma company InCarda Therapeutics as executive chairman. 3 April 2019
The Pan American Health Organization (PAHO) and non-profit PATH have published a report detailing the opportunities to improve vaccine programs through effective data use. 3 April 2019
Bristol-Myers Squibb has presented new survival data for Opdivo (nivolumab) at the annual meeting of the American Association for Cancer Research (AACR). 3 April 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024